• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's Pre-Market Session

    6/21/24 8:08:00 AM ET
    $ASLN
    $CASI
    $CYCN
    $DMTK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ASLN alert in real time by email

    Gainers

    • DermTech (NASDAQ:DMTK) stock rose 56.6% to $0.18 during Friday's pre-market session. The market value of their outstanding shares is at $6.4 million.
    • Sarepta Therapeutics (NASDAQ:SRPT) shares rose 39.26% to $171.99. The market value of their outstanding shares is at $16.2 billion.
    • Kintara Therapeutics (NASDAQ:KTRA) shares increased by 17.78% to $0.32. The market value of their outstanding shares is at $17.9 million.
    • Solid Biosciences (NASDAQ:SLDB) stock moved upwards by 17.3% to $7.39. The market value of their outstanding shares is at $283.6 million.
    • ASLAN Pharma (NASDAQ:ASLN) stock rose 14.06% to $0.36. The market value of their outstanding shares is at $8.2 million.
    • Alaunos Therapeutics (NASDAQ:TCRT) shares moved upwards by 13.43% to $0.71. The company's market cap stands at $11.3 million.

    Losers

    • Psyence Biomedical (NASDAQ:PBM) stock fell 23.9% to $0.46 during Friday's pre-market session. The company's market cap stands at $6.1 million.
    • CASI Pharmaceuticals (NASDAQ:CASI) shares fell 23.72% to $2.67. The company's market cap stands at $35.7 million.
    • Sonnet BioTherapeutics (NASDAQ:SONN) shares declined by 16.4% to $0.87. The company's market cap stands at $2.7 million.
    • Cyclerion Therapeutics (NASDAQ:CYCN) shares decreased by 14.04% to $1.96. The market value of their outstanding shares is at $4.8 million.
    • Scinai Immunotherapeutics (NASDAQ:SCNI) shares decreased by 11.48% to $3.47. The company's market cap stands at $2.0 million.
    • Sonoma Pharmaceuticals (NASDAQ:SNOA) stock fell 10.69% to $0.18. The market value of their outstanding shares is at $3.4 million. As per the news, the Q4 earnings report came out 4 days ago. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ASLN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ASLN
    $CASI
    $CYCN
    $DMTK

    CompanyDatePrice TargetRatingAnalyst
    Sarepta Therapeutics Inc.
    $SRPT
    1/28/2026$20.00Equal Weight
    Barclays
    Sarepta Therapeutics Inc.
    $SRPT
    12/9/2025$32.00Outperform
    Wedbush
    Solid Biosciences Inc.
    $SLDB
    12/4/2025$16.00Buy
    Needham
    Sarepta Therapeutics Inc.
    $SRPT
    11/5/2025$26.00Neutral → Outperform
    Mizuho
    Sarepta Therapeutics Inc.
    $SRPT
    9/22/2025$50.00Market Perform → Outperform
    BMO Capital Markets
    Sarepta Therapeutics Inc.
    $SRPT
    7/29/2025$22.00Underweight → Equal Weight
    Barclays
    Sarepta Therapeutics Inc.
    $SRPT
    7/29/2025$13.00Mkt Perform
    Bernstein
    Sarepta Therapeutics Inc.
    $SRPT
    7/29/2025$37.00Perform → Outperform
    Oppenheimer
    More analyst ratings

    $ASLN
    $CASI
    $CYCN
    $DMTK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kahn Clare bought $9,924 worth of shares (1,860 units at $5.34), increasing direct ownership by 169% to 2,960 units (SEC Form 4)

    4 - Solid Biosciences Inc. (0001707502) (Issuer)

    3/13/25 4:05:03 PM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Bain Capital Life Sciences Investors, Llc bought $4,030,000 worth of shares (1,000,000 units at $4.03) (SEC Form 4)

    4 - Solid Biosciences Inc. (0001707502) (Issuer)

    2/21/25 5:48:02 PM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Perceptive Advisors Llc bought $20,150,000 worth of shares (5,000,000 units at $4.03) (SEC Form 4)

    4 - Solid Biosciences Inc. (0001707502) (Issuer)

    2/21/25 4:17:42 PM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ASLN
    $CASI
    $CYCN
    $DMTK
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for AMONDYS 45 issued to SAREPTA THERAPS INC

    Submission status for SAREPTA THERAPS INC's drug AMONDYS 45 (SUPPL-8) with active ingredient CASIMERSEN has changed to 'Approval' on 07/11/2024. Application Category: NDA, Application Number: 213026, Application Classification: Labeling

    7/12/24 4:40:36 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    June 20, 2024 - FDA Expands Approval of Gene Therapy for Patients with Duchenne Muscular Dystrophy

    For Immediate Release: June 20, 2024 Today, the U.S. Food and Drug Administration expanded the approval of Elevidys (delandistrogene moxeparvovec-rokl), a gene therapy for the treatment of Duchenne muscular dystrophy (DMD) for ambulatory and non-ambulatory individuals 4 years of age and older with DMD with a confirmed mutation in the DMD gene.  Elevidys was previously approved under accelerated approval for amb

    6/20/24 5:24:42 PM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for VYONDYS 53 issued to SAREPTA THERAPS INC

    Submission status for SAREPTA THERAPS INC's drug VYONDYS 53 (SUPPL-11) with active ingredient GOLODIRSEN has changed to 'Approval' on 06/04/2024. Application Category: NDA, Application Number: 211970, Application Classification: Labeling

    6/5/24 4:41:31 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASLN
    $CASI
    $CYCN
    $DMTK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays resumed coverage on Sarepta Therapeutics with a new price target

    Barclays resumed coverage of Sarepta Therapeutics with a rating of Equal Weight and set a new price target of $20.00

    1/28/26 7:19:11 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wedbush initiated coverage on Sarepta Therapeutics with a new price target

    Wedbush initiated coverage of Sarepta Therapeutics with a rating of Outperform and set a new price target of $32.00

    12/9/25 8:53:25 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Needham initiated coverage on Solid Biosciences with a new price target

    Needham initiated coverage of Solid Biosciences with a rating of Buy and set a new price target of $16.00

    12/4/25 8:48:04 AM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ASLN
    $CASI
    $CYCN
    $DMTK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Psyence BioMed Announces Exercise of Put Option by PsyLabs and Strategic Equity Investment

    NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced that Psyence Labs Ltd., a leading developer and manufacturer of pharmaceutical-grade psychedelic compounds ("PsyLabs") has exercised its rights under a previously disclosed put option agreement (the "Put Option Agreement"), pursuant to which Psyence BioMed will make an equity investment in PsyLabs at a fair market value determined in accordance with the terms of the Put Option Agreement. The Put Option Agreement was previously disclosed by P

    2/20/26 5:20:00 PM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Psyence BioMed Announces Results of Annual and Special Meeting of Shareholders

    NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced the voting results from its Annual and Special Meeting of Shareholders (the "Meeting"), held at 9:00 a.m. Eastern Time on February 12, 2026. Shareholders voted in favour of all matters of business presented at the Meeting, including the election of directors, the appointment of auditors and the approval of share consolidation authority for the board of directors (the "Board"). All director nominees listed in the Company's management informat

    2/17/26 9:15:00 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Scinai Announces Completion of Acquisition of Recipharm Israel Ltd. and Strategic Commercial Collaboration with Recipharm

    JERUSALEM, Feb. 17, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) ("Scinai", or the "Company"), a biopharmaceutical company developing inflammation and immunology (I&I) therapeutics and operating a growing CDMO business, today announced that it has acquired 100% of the shares of Recipharm Israel Ltd., which operates Recipharm's site in Yavne, Israel, and entered into a long-term strategic commercial collaboration with Recipharm. The transactions significantly expand Scinai's manufacturing footprint, capabilities, and commercial positioning, strengthening its

    2/17/26 7:00:00 AM ET
    $SCNI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ASLN
    $CASI
    $CYCN
    $DMTK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Cumbo Alexander converted options into 30,031 shares and sold $96,923 worth of shares (16,644 units at $5.82), increasing direct ownership by 6% to 235,405 units (SEC Form 4)

    4 - Solid Biosciences Inc. (0001707502) (Issuer)

    2/18/26 9:38:15 PM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Regulatory Officer Hanrahan Jessie converted options into 8,125 shares and sold $24,074 worth of shares (4,134 units at $5.82), increasing direct ownership by 6% to 74,318 units (SEC Form 4)

    4 - Solid Biosciences Inc. (0001707502) (Issuer)

    2/18/26 9:34:09 PM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Ganot Ilan converted options into 4,861 shares and sold $15,478 worth of shares (2,658 units at $5.82) (SEC Form 4)

    4 - Solid Biosciences Inc. (0001707502) (Issuer)

    2/18/26 9:32:55 PM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ASLN
    $CASI
    $CYCN
    $DMTK
    SEC Filings

    View All

    SEC Form 6-K filed by Psyence Biomedical Ltd.

    6-K - PSYENCE BIOMEDICAL LTD. (0001985062) (Filer)

    2/20/26 5:25:01 PM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by CASI Pharmaceuticals Inc.

    6-K - CASI Pharmaceuticals, Inc. (0001962738) (Filer)

    2/20/26 9:00:13 AM ET
    $CASI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by CASI Pharmaceuticals Inc.

    6-K - CASI Pharmaceuticals, Inc. (0001962738) (Filer)

    2/19/26 9:00:37 AM ET
    $CASI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASLN
    $CASI
    $CYCN
    $DMTK
    Financials

    Live finance-specific insights

    View All

    Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results

    Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-year 2025 financial results after the Nasdaq Global Market closes on Wednesday, Feb. 25, 2026. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its fourth quarter and full-year 2025 financial results. The event will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarepta.com/events-presentations and following the event a replay will be archived there for one year. Interested parties participating by phone will need to register using this online form. After register

    2/11/26 8:30:00 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients

    At a mean age of 9 years old, ELEVIDYS-treated patients achieved mean North Star Ambulatory Assessment (NSAA) scores above baseline three years after treatment (n=52) ELEVIDYS gene therapy demonstrated 70% or greater reduction in the rate of decline relative to the propensity-weighted external control group, as measured by Time to Rise (TTR) and 10-meter walk/run (10MWR). ELEVIDYS-treated patients showed an increasing treatment effect over time, with the functional gap versus the external control group significantly widening between Year 2 and Year 3 No new treatment-related safety signals were observed, consistent with the manageable safety profile observed with ELEVIDYS in ambulato

    1/26/26 8:00:00 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sarepta Therapeutics to Report 3-Year Topline Data from EMBARK Study of ELEVIDYS Gene Therapy in Ambulatory Individuals with Duchenne Muscular Dystrophy

    Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Monday, Jan. 26, 2026, at 8:30 am Eastern Time, the Company will host a webcast and conference call to present 3-year topline functional results from patients treated in Part 1 of EMBARK (Study 9001-301), the global, randomized placebo-controlled Phase 3 study evaluating ELEVIDYS (delandistrogene moxeparvovec-rokl) in ambulatory individuals with Duchenne muscular dystrophy who were aged four to seven at time of treatment. The event will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarepta.com/events-presenta

    1/23/26 4:05:00 PM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASLN
    $CASI
    $CYCN
    $DMTK
    Leadership Updates

    Live Leadership Updates

    View All

    Psyence BioMed Announces Results of Annual and Special Meeting of Shareholders

    NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced the voting results from its Annual and Special Meeting of Shareholders (the "Meeting"), held at 9:00 a.m. Eastern Time on February 12, 2026. Shareholders voted in favour of all matters of business presented at the Meeting, including the election of directors, the appointment of auditors and the approval of share consolidation authority for the board of directors (the "Board"). All director nominees listed in the Company's management informat

    2/17/26 9:15:00 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board

    –Received Positive Pre-Investigational New Drug ("IND") Written Feedback from the U.S. Food and Drug Administration ("FDA")– –Clinical Advisory Board ("CAB") Includes Key Leaders across Neuropsychiatry, Anesthesiology, and Clinical Development– –Remain On Track to Initiate CYC-126's Phase 2 Proof-of-Concept ("POC") Study in Treatment Resistant Depression ("TRD") in the Second Half of 2026– CAMBRIDGE, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) ("Cyclerion" or "Company"), a biopharmaceutical company pioneering neuropsychiatric therapies, today announced it has received positive written regulatory feedback and responses from the FDA on CYC-126

    2/17/26 7:00:00 AM ET
    $CYCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Psyence BioMed Achieves Milestone in Natural Ibogaine HCl Production and Strengthens Balance Sheet With No Debt and $12m Cash

    NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced a significant scientific and manufacturing achievement. Through its investment in PsyLabs, Psyence BioMed has become the first Nasdaq-listed company to produce GMP-compliant, high-purity ibogaine hydrochloride (Ibogaine HCl) derived from a naturally extracted, ethically sourced supply in Africa. Ibogaine HCl is the purified, stabilised, crystalline salt form of ibogaine used in clinical and therapeutic settings and represents the standard ph

    1/5/26 9:15:00 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASLN
    $CASI
    $CYCN
    $DMTK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Psyence Biomedical Ltd.

    SC 13G - PSYENCE BIOMEDICAL LTD. (0001985062) (Subject)

    12/13/24 9:16:01 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Psyence Biomedical Ltd.

    SC 13G/A - PSYENCE BIOMEDICAL LTD. (0001985062) (Subject)

    12/9/24 1:36:43 PM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Psyence Biomedical Ltd.

    SC 13G/A - PSYENCE BIOMEDICAL LTD. (0001985062) (Subject)

    12/4/24 4:38:27 PM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care